Previous 10 | Next 10 |
Savara Inc. (NASDAQ: SVRA) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.68% on the day to $3.33. Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-...
Savara Inc. (NASDAQ: SVRA) is the focus of IBN's latest stock spotlight. The company's shares have moved 2.67% on the day to $3.27. Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-...
Savara Inc. (NASDAQ: SVRA) is the focus of IBN's latest stock spotlight. The company's shares have moved -0.14% on the day to $3.67. Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte...
2023-10-05 17:23:44 ET Gainers: nCino ( NASDAQ: NCNO ) +8% . TPI Composites ( TPIC ) +6% . SCYNEXIS ( SCYX ) +5% . Sutro Biopharma ( STRO ) +5% . Black Diamond Therapeutics ( BDTX ) +4% . Losers: SomaLogic ( SLGC ...
Savara Inc. (NASDAQ: SVRA) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.49% on the day to $3.75. Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-...
2023-09-13 09:34:50 ET Summary Savara focuses on rare respiratory diseases, with lead product molgramostim in Phase 3 for autoimmune Pulmonary Alveolar Proteinosis (aPAP). Financially stable with $185.2M in liquidity, but increased R&D expenses signal a risky, all-in approach ...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright 25 th Annual Global Investment Conference on September 12, 2023 at 3:30pm ET/12:30pm PT. A live webcast o...
2023-08-10 17:20:13 ET Savara press release ( NASDAQ: SVRA ): Q2 GAAP EPS of -$0.07 beats by $0.01 . $105M in Cash and Cash Equivalents at the End of 2Q 2023 For further details see: Savara GAAP EPS of -$0.07 beats by $0.01
Fully Enrolled Pivotal Phase 3 IMPALA-2 Trial Remains On-Track to Report Top Line Data by End of 2Q 2024 — 48-week placebo-controlled trial is evaluating molgramostim nebulizer solution (molgramostim), a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Prote...
2023-07-16 11:50:23 ET Summary Today, we circle back on a small development firm called Savara for the first time in over two years. Its primary drug candidate is being developed for a rare affliction that has no approved therapies and has a pivotal readout coming up in the second...
News, Short Squeeze, Breakout and More Instantly...
Pivotal Phase 3 IMPALA-2 Trial Remains On-track, Top Line Results Expected by End of 2Q 2024 48-week placebo-controlled trial is evaluating molgramostim nebulizer solution (molgramostim), a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP), a ra...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Citizens JMP Life Science Conference on May 14, 2024 at 6:00am PT/9:00am ET. A live webcast of the fir...
Savara’s Partner, Trillium Health LLC, to Present Data on the Laboratory Blood Test for Diagnosing aPAP Company to Host Industry Theater on Pulmonary Alveolar Proteinosis (PAP) with Two World-Renowned Experts Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage ...